Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2023-03-08 00:00:00 ET · period of report 2023-03-07 · accession 0001209191-23-017148 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-08 | 2023-03-07 | TRVI | Simon Farrell | Chief Commercial Off | M - OptEx | $0.51 | +18.8K | 39.4K | +91% | +$9,562 |
| D | 2023-03-08 | 2023-03-07 | TRVI | Simon Farrell | Chief Commercial Off | M - OptEx | $0.00 | -18.8K | 56.2K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-07 | M | A | 18,750 | $0.51 | 39,400 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-03-07 | M | D | 18,750 | $0.00 | 56,250 | D | $0.51 · — to 2032-02-10 | 18,750 Common Stock | (F1) This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |